Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria

• Status: Completed
• Trial end date: 2017-02-02
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the efficacy and safety of imatinib in combination with dihydroartemisinin plus piperaquine in the treatment uncomplicated P. falciparum malaria in adult male patients.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: HuLow
• Collaborators: Hue University; Purdue University; Università degli Studi di Sassari; University of Turin, Italy
• Treatments: Artemisinins; Artenimol; Dihydroartemisinin; Imatinib Mesylate; Piperaquine

Criteria

Inclusion Criteria:

• Gender: only adults are selected for the trial; note that female subjects cannot be women of child-bearing age.

• Age: 18-50 years.

• Target disease: Uncomplicated Plasmodium falciparum malaria

Exclusion Criteria:

• symptoms and signs of complicated malaria

• including continuous high fever of over 390C, psychiatric disorders, confusion, other neurological symptoms, symptoms and signs of functional impairment of the organs such as lungs, kidneys or cardiovascular system;

• symptoms and signs of liver damage or kidney damage

• symptoms and signs of another complicating infection such as pneumonia, dengue fever, and other bacterial infection.

• P. falciparum > 25.000 / mm3

• WBC <4000 and >10.000 /mm3

• RBC < 3.5x106/mm3

• Platelets < 40.000 /mm3

• Hemoglobin < 10 g/dL

• ALT more than 200% of the upper limit (56 units/L)

• AST more than 200% of the upper limit (40 units/L)

• Blood creatine more than 75% of the upper limit (men: 1.2 mg/dL, women 1 mgdL)

• Serum total protein < 6 g/L

• Glycemia < 50 mg/dL> 200 mg/dL

• Standard urine test Serious alterations

• Concomitant treatments

Antimalarial Drugs Anticoagulant therapy